
FORTUNE UNVEILS 2025 SOUTHEAST ASIA 500
2 nd annual Fortune list has Singapore's Trafigura at No. 1, as the energy sector dominates; Malaysia's NationGate claims fastest growing by revenue
Ranks of female CEOs at Southeast Asia 500 companies increases to nearly 40, up 28% from last year
Indonesia has the most companies, 109, on the Southeast Asia 500 but Singapore companies lead in revenue, profits, and assets
SINGAPORE, June 17, 2025 /PRNewswire/ -- Fortune today unveils the 2025 Southeast Asia 500 rankings, the second annual list of the largest companies in the region, ranked by revenue for the 2024 fiscal year. Fortune's focus on Southeast Asia comes as the region emerges as a resilient growth engine for the global economy, playing an increasingly important role in global supply chains, capturing manufacturing capacity shifting from China due to heightened tariffs and trade tensions.
The seven countries in last year's inaugural Southeast Asia 500 list—Indonesia, Thailand, Malaysia, Singapore, Vietnam, the Philippines, and Cambodia—return in 2025, and continue to make their mark on the region's economy. Indonesia leads with 109 companies, while Thailand follows with 100. Malaysia has 92 companies on the list, surpassing Singapore's 81. Vietnam's presence on the list has grown to 76, while the Philippines contributes 40 and Cambodia rounds out the list with two.
Singapore-headquartered commodities trader Trafigura earned the No. 1 spot on the Fortune Southeast Asia 500 for a second year, generating more than $243 billion in revenue in 2024, followed by Thailand's PTT (No. 2), Indonesia's Pertamina (No. 3) and Singapore's food and agribusiness powerhouses— Wilmar (No. 4) and Olam (No. 5). The top five companies generated nearly $516 billion in revenue, or 28% of all 500 companies combined.
Together, the top 10 generated $660 billion—36% of the list's total revenue—while the top 20 accounted for $836 billion, nearly half the combined revenue of all 500 companies. Notably, Singapore-based companies generated $637 billion in 2024, underscoring the city-state's role as a regional business hub and accounting for just over a third of the Southeast Asia 500's total revenue. Collectively, companies on the 2025 list generated $1.82 trillion in revenue in 2024, up from $1.79 trillion the year before. The minimum revenue threshold to be included on the 2025 list was $349.4 million.
"Fortune's interest in the region reflects Southeast Asia's growing importance as an engine of global growth," says Clay Chandler, Executive Editor, Asia. "The region has become a crucial manufacturing and export hub, which is drawing significant capital flows. This momentum has been further fueled by Trump-era tariffs, which have reshaped global trade dynamics and driven a shift towards Southeast Asia."
Energy – whether resource extraction, power generation, or electrical transmission—is the dominant sector on the 2025 list, accounting for almost a third of its total revenue. Thai oil refiner and energy company, Bangchak, breaks into this year's top 20 with a 47% jump in revenue. Financial firms represent Southeast Asia's second-largest sector. Significantly, thirteen banks and financial firms are among the top 20 most profitable companies with Singapore's DBS leading—both in terms of revenue and earnings—for a second year.
In his introduction to the new list in the June/July issue of Fortune Asia magazine, editor, Asia, Nick Gordon notes, the Fortune Southeast Asia 500 provides "a snapshot of a region ready to take advantage of global supply chain shifts and booming industries like mining, EVs, and AI—even as U.S. tariff policy threatens to roll back some of last year's gains."
Fast-growers in revenue terms included newcomers to the list—Malaysian precision manufacturing company NationGate, Indonesian mining and energy firm, Petrindo Jaya Kreasi and Vietnam's transport infrastructure and automotive services company, Tasco JSC, as well as returning companies such as the Philippines' online gaming firm, Digiplus Interactive, and travel and transportation companies like Singapore aviation catering and logistics firm SATS, Changi Airport Group and Airports of Thailand. In 2024, the top 20 fast-growers captured strong tailwinds from rebounding tourism, resource demand (coal, nickel, energy), digital transformation, and industrial growth in Southeast Asia.
In a positive sign for female leadership in the region, Fortune's analysts noted there are 37 female CEOs leading Southeast Asia 500 companies, up from 29 reported last year. There are also 37 women holding the position of chairman. This growth in diversity, alongside the ten CEOs in their 30s, underscores the region's evolving leadership landscape. The average age of the chief executives leading the 500 companies is 58. In total, the 2025 Southeast Asia 500 companies employ more than 6.3 million people.
The 2025 Fortune Southeast Asia 500 list and stories are available internationally on Fortune.com/asia and on newsstands across Asia starting today, June 17. The list and rankings can be viewed at https://fortune.com/asia/ranking/southeast-asia-500/2025/.
Fortune is a global multi-platform media company built on a legacy of trusted, award-winning reporting and information for those who want to make business better. Independently owned, Fortune tells the stories of the world's biggest companies and their leaders as well as a new generation of innovators who are moving business forward. Digitally and in print, Fortune measures corporate performance through rigorous benchmarks, and holds companies accountable, in regions around the world. Its iconic rankings include Fortune 500, Fortune Global 500, Most Powerful Women, and World's Most Admired Companies. Fortune builds world-class communities by convening industry thought leaders for exclusive summits and conferences, including the Fortune Global Forum and Brainstorm Tech. For more information, visit fortune.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F22%2Fnews-p.v1.20250622.6f347ba79b0f48699e57a8849a11dca7_T1.jpg&w=3840&q=100)
![[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75)
Korea Herald
6 hours ago
- Korea Herald
[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts
Korea Herald correspondent BOSTON — SK Biopharmaceuticals CEO Lee Dong-hoon underscored the company's preparedness for potential US tariff changes and emphasized the critical role of open innovation in shaping the future of global pharmaceuticals. 'We've weathered volatility in our share price over the past year, but the impact of potential price cuts has been minimal,' Lee said Thursday during a press conference on the sidelines of the 2025 Bio USA. 'Our direct-to-market sales model remains fundamentally solid.' He recalled a particularly tense moment earlier this year when shifting US tariff policies posed logistical challenges. In April, the company rushed to transport finished products from Canada into the US before a new tariff deadline. 'When the final truck finally cleared customs, everyone burst into applause,' he recounted. To prevent such risks from recurring, the company now assembles finished products in Canada and ensures shipments cross the border ahead of any policy changes. Looking ahead, SK Biopharmaceuticals is evaluating Puerto Rico as a potential US-based manufacturing site, leveraging its status as a US territory and pharmaceutical hub. 'Canada is cost-effective for now, but we're preparing for every scenario,' Lee said, noting the company's tariff risk is now 'close to zero' for the year. Lee also expressed confidence in the company's long-term growth. 'We've already announced our goal to hit 1 trillion won ($728 million) in sales by 2029, and we're on track,' he said, citing consistent profitability since last year. A cornerstone of SK Biopharmaceuticals' strategy is open innovation. Instead of relying solely on internal research and development, the company is partnering with universities, biotech firms and research institutions. 'Major global pharmaceutical firms are moving away from in-house basic research, and so are we. When you can collaborate and generate results at a fraction of the cost, your possibilities expand," he explained. The CEO emphasized the importance of tapping into underutilized technologies at US universities and biotech startups to diversify the company's pipeline, moving beyond its core focus on epilepsy into areas like oncology. Artificial intelligence is another major focus area. Lee highlighted the company's work on EEG-based seizure prediction models in collaboration with European and South American partners, along with AI algorithm development trials currently underway in Korea. 'AI is no longer optional. It's essential in every part of the business,' he said. One standout partnership is with PhnyX Lab, whose AI-driven automation of clinical documentation significantly reduced paperwork. 'Even our US team, which was initially skeptical, was blown away,' Lee said, calling the shift 'Copernican' in scale for how it will reduce time and cost. The CEO also outlined plans to build a global digital platform for epilepsy patients — a space where patients and physicians can share experiences and insights. 'It's not about selling drugs,' he clarified. 'It's about collecting data to inform AI-powered marketing, drug development and clinical trial design.' The company is looking three to five years ahead, aiming to build an ecosystem where shared data drives innovation across functions. In the US, SK Biopharmaceuticals is intensifying its engagement with health care providers. Lee has personally met with dozens of physicians this year, aiming for 100 meetings, to gather insights that will shape lifecycle strategies such as patent extensions, expanded indications and new formulations like IV delivery. Meanwhile, SK Biopharmaceuticals has invested in targeted TV and YouTube campaigns for its flagship epilepsy drug, Xcopri (cenobamate). Its 'Road to Reduction' campaign drew 9.37 million views in just one month, signaling the brand's growing visibility and leadership in the epilepsy treatment market.


Korea Herald
9 hours ago
- Korea Herald
HD Hyundai partners with Edison Chouest Offshore to build LNG dual-fuel container ships
Korean shipbuilding giant HD Hyundai announced Sunday that it has signed a strategic and comprehensive partnership with US-based Edison Chouest Offshore to jointly build LNG dual-fuel container ships in the United States. This initiative follows HD Hyundai's recent agreements with major US defense firms and academic institutions. The signing ceremony took place on Thursday at ECO's headquarters in New Orleans, Louisiana, attended by key officials from both companies. Under the deal, HD Hyundai and ECO plan to jointly construct medium-sized container ships at ECO's shipyards by 2028. HD Hyundai will provide support for ship design, equipment procurement and construction technology. It also plans to produce and supply ship blocks and invest in related technological assets. Both companies are exploring expanded cooperation in additional vessel types and port cranes, which are considered critical for US national security. ECO operates five shipyards across the US and manages a fleet of 300 offshore support vessels, positioning it as a major player in the OSV sector. The partnership follows a sluggish period for US shipbuilding, with domestic firms receiving orders for only three 3,600 twenty-foot equivalent unit container ships from 2022 to 2024, according to shipping market analysis firm Clarkson Research. 'The United States is a strong ally and an important business partner,' an HD Hyundai spokesperson said. 'Through this collaboration, we aim to support the revival of its shipbuilding industry and bolster its national security.'


Korea Herald
2 days ago
- Korea Herald
Trump repeats NATO members should spend 5% of GDP on defense
US President Donald Trump reiterated Friday that North Atlantic Treaty Organization member states should spend 5 percent of gross domestic product on defense, while saying the United States should not. Trump made the remarks during a press availability as he is preparing to attend a NATO summit in The Hague, the Netherlands, next week, where the defense spending target is expected to figure prominently. "I don't think we should, but I think they should," he said, responding to a question about the defense spending target that he proposed. "We've been supporting NATO so long. In many cases, I believe ... almost paying 100 percent of the cost. So I don't think we should, but I think that the NATO countries should absolutely," he added. The US spent about 3.4 percent of its GDP on defense last year. Asked about Spain's stance against the target, Trump said that NATO will have to deal with the country. "Spain has been a very low payer," he said. "They were either good negotiators or they weren't doing the right thing. I mean I think Spain has to pay what everybody else has to pay. Spain has been notorious for low pay." Spain has reportedly rejected the defense spending proposal, calling for a more "flexible" approach. On Thursday, the Pentagon said that European allies are setting the "global standard" for Asian allies, which is spending 5 percent of GDP on defense. South Korea's defense budget this year stands at around 61.2 trillion won ($44.6 billion), which is about 2.32 percent of its GDP, according to Seoul's defense ministry. (Yonhap)